Geodon/Zeldox (Schizophrenia) - Analysis and Forecasts to 2020

Geodon/Zeldox (Schizophrenia) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Geodon (Schizophrenia) - Analysis and Forecasts to 2020” provides Geodon sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Geodon including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Geodon including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Geodon in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Geodon – Analysis and Forecasts from 2002 to 2017 1
2 Table of contents 2
2.1 List of Tables 3
2.2 List of Figures 3
3 Introduction 4
3.1 Schizophrenia 4
3.2 Symptoms 4
3.3 Schizophrenia Market 4
3.4 Epidemiology 4
3.5 Etiology 5
3.5.1 Genetic Factors 5
3.5.2 Environmental Factors 5
3.5.3 Abnormal Brain Structure 6
3.6 GlobalData Report Guidance 6
4 Schizophrenia: Market Characterization 7
4.1 Schizophrenia Market 7
4.2 Schizophrenia Market Forecasts and CAGR 7
4.3 Drivers of Schizophrenia Therapeutics Market 7
4.3.1 Patent Expiry of Leading Marketed Drugs 8
4.3.2 Increasing Patient Pool 8
4.3.3 High Prescription Rates 8
4.3.4 Low Patient Compliance Rate 8
4.3.5 High Unmet Need 8
5 Classification of Schizophrenia 9
5.1 Age of Onset of Schizophrenia 9
5.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
5.1.2 Adult Schizophrenia 10
5.2 Associated Symptoms 10
5.2.1 Paranoid Schizophrenia 10
5.2.2 Disorganized Schizophrenia 10
5.2.3 Catatonic Schizophrenia 10
5.2.4 Residual Schizophrenia 10
5.2.5 Undifferentiated Disorder 10
6 Treatment for Schizophrenia 11
6.1 Crisis Resolution Teams (CRT) 11
6.2 Voluntary and Compulsory Detention 11
6.3 Antipsychotics 11
7 Geodon/ Zeldox 13
7.1 Introduction 13
7.2 Mechanism of Action 13
7.3 Clinical Studies 13
7.4 Approval History 14
7.5 Factors Affecting Sales of Geodon 14
7.5.1 Generic Erosion 14
7.5.2 Weight Gain 14
7.5.3 Lowest Efficacy 14
7.5.4 High Competition 14
7.6 Drug Risk Benefit Score 15
7.6.1 Efficacy 15
7.6.2 Safety 15
7.6.3 Compliance 16
7.6.4 Dosing Convenience 16
7.7 Intensity of Competition 16
7.8 Sales forecast 16
7.8.1 Target Patient Pool of Geodon 16
7.8.2 Dosing 16
7.8.3 Market Penetration 17
7.8.4 Annual Cost of Therapy 17
7.8.5 Sales Projections of Geodon 17
8 Schizophrenia Market: Appendix 26
8.1 Market Definitions 26
8.2 Abbreviations 26
8.3 Research Methodology 26
8.4 Contact Us 28
8.5 Disclaimer 29
8.6 Sources 29